Live Quote · NASDAQSLRNHealthcare· Biotechnology

Acelyrin, Inc.

$2.27 0.00%(+$0.00)
TickerSpark Score
56/100
Mixed
87
Valuation
20
Profitability
60
Growth
84
Health
30
Momentum

Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a SLRN research report →

52-Week Range8% of range
Low
$1.84
Current
$2.27
High
$7.25
Company Overviewwww.acelyrin.com

About the company

Acelyrin, Inc. is a biopharmaceutical company focused on discovering, obtaining, and rapidly advancing the development and commercialization of innovative medical therapies. The firm's most advanced experimental drug is izokibep, a potent small protein therapeutic specifically designed to block IL-17A.

CEO
Mina Kim
IPO
2023
Employees
83
HQ
Agoura Hills, CA, US

Price Chart

-47.58% · this period
$7.06$4.47$1.89May 21Nov 19May 22
Valuation
Market Cap
$229.17M
P/E
-0.91
P/S
0.00
P/B
0.49
EV/EBITDA
-0.65
Div Yield
0.00%
Profitability
Gross Margin
0.00%
Op Margin
0.00%
Net Margin
0.00%
ROE
-44.54%
ROIC
-68.08%
Growth & Income
Revenue
$0 · 0.00%
Net Income
$-248,226,000 · 34.96%
EPS
$-2.50 · 53.96%
Op Income
$-316,258,000
FCF YoY
-67.68%
Performance & Tape
52W High
$7.25
52W Low
$1.84
50D MA
$2.40
200D MA
$3.55
Beta
1.09
Avg Volume
997.03K

Get TickerSpark's AI analysis on SLRN

Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.

Get Pro Access →

Already have an account? Log in

Form 4 · Filings

Recent insider transactions

Who's buying, who's selling, and how much.

DateInsiderTypeShares
May 21, 25AyurMaya Capital Management Company, LPsell9,334,735
May 21, 25Kim Minaother89,526
May 21, 25Kim Minasell190,114
May 21, 25Kim Minasell770,833
May 21, 25Kim Minasell1,195,856
May 21, 25Kim Minasell85,226
May 21, 25Kim Minasell362,719
May 21, 25COZADD BRUCE Csell92,158
May 21, 25COZADD BRUCE Csell183,434
May 21, 25COZADD BRUCE Csell23,243
Coverage · SLRN

Our SLRN coverage

Recent articles, reports, and earnings notes.

On-Demand Research

No research on SLRN yet

For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.

Generate SLRN report →
Internal Compare

Similar companies

Peers in the same neighborhood.